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Biannual azithromycin distribution has been shown to reduce child mortality as well as
increase antimicrobial resistance. Targeting distributions to vulnerable subgroups such as
malnourished children is one approach to reaching those at the highest risk of mortality
while limiting selection for resistance. The objective of this analysis was to assess whether
the effect of azithromycin on mortality differs by nutritional status.
Methods and findings
A large simple trial randomized communities in Niger to receive biannual distributions of azi-
thromycin or placebo to children 1–59 months old over a 2-year timeframe. In exploratory
subgroup analyses, the effect of azithromycin distribution on child mortality was assessed
for underweight subgroups using weight-for-age Z-score (WAZ) thresholds of −2 and −3.
Modification of the effect of azithromycin on mortality by underweight status was examined
on the additive and multiplicative scale. Between December 2014 and August 2017, 27,222
children 1–11 months of age from 593 communities had weight measured at their first study
visit. Overall, the average age among included children was 4.7 months (interquartile range
[IQR] 3–6), 49.5% were female, 23% had a WAZ < −2, and 10% had a WAZ < −3. This anal-
ysis included 523 deaths in communities assigned to azithromycin and 661 deaths in com-
munities assigned to placebo. The mortality rate was lower in communities assigned to
azithromycin than placebo overall, with larger reductions among children with lower WAZ:
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−12.6 deaths per 1,000 person-years (95% CI −18.5 to −6.9, P < 0.001) overall, −17.0 (95%
CI −28.0 to −7.0, P = 0.001) among children with WAZ < −2, and −25.6 (95% CI −42.6 to
−9.6, P = 0.003) among children with WAZ < −3. No statistically significant evidence of effect
modification was demonstrated by WAZ subgroup on either the additive or multiplicative
scale (WAZ < −2, additive: 95% CI −6.4 to 16.8, P = 0.34; WAZ < −2, multiplicative: 95% CI
0.8 to 1.4, P = 0.50, WAZ < −3, additive: 95% CI −2.2 to 31.1, P = 0.14; WAZ < −3, multipli-
cative: 95% CI 0.9 to 1.7, P = 0.26). The estimated number of deaths averted with azithro-
mycin was 388 (95% CI 214 to 574) overall, 116 (95% CI 48 to 192) among children with
WAZ < −2, and 76 (95% CI 27 to 127) among children with WAZ < −3. Limitations include
the availability of a single weight measurement on only the youngest children and the lack of
power to detect small effect sizes with this rare outcome. Despite the trial’s large size, formal
tests for effect modification did not reach statistical significance at the 95% confidence level.
Conclusions
Although mortality rates were higher in the underweight subgroups, this study was unable to
demonstrate that nutritional status modified the effect of biannual azithromycin distribution
on mortality. Even if the effect were greater among underweight children, a nontargeted
intervention would result in the greatest absolute number of deaths averted.
Trial registration
The MORDOR trial is registered at clinicaltrials.gov NCT02047981.
Author summary
Why was this study done?
• Previous research has found that distributing oral azithromycin to children 1–59
months old biannually reduces mortality in that age group.
• Despite the promise of this intervention to promote child survival in high-mortality set-
tings, community distribution of antibiotics like azithromycin has the potential to
increase antimicrobial resistance, which could reduce the efficacy of azithromycin and
similar antibiotics over time.
• To harness the benefit of the intervention while reducing the potential for increasing
resistance, some propose targeting the intervention to smaller groups of the population
that face a particularly high risk of mortality.
• As malnutrition is implicated in a large proportion of childhood mortality, malnour-
ished children are one potential subgroup to target.
What did the researchers do and find?
• We conducted a subgroup analysis using data from a trial that compared communities
randomized to azithromycin distribution or placebo distribution to children 1–59
months over 2 years in Niger.
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• We included 27,222 children from the original trial who had weight measured at their
first study visit and compared the effect of azithromycin to placebo on mortality among
those who were not underweight, were underweight, and were severely underweight,
and we calculated the number of deaths that would have been averted if this interven-
tion had been given to the overall group as well as these groups defined by underweight
status.
• The observed effect of azithromycin on mortality was strongest in the severely under-
weight subgroup, but we found no statistical evidence that the effect differed by under-
weight status.
• As only 10% of children were in the severe underweight group, the overall number of
deaths averted would be greatest with an intervention treating all children 1–11 months,
rather than only underweight children.
What do these findings mean?
• The mortality rates and the observed effect of azithromycin on mortality were largest
for the severe underweight group, suggesting a potential group to target with this inter-
vention, although the study was not powered to detect this effect.
• Even if this study provided evidence that the effect was strongest among underweight
children, a nontargeted intervention would have prevented the greatest number of
deaths in this population.
Introduction
Biannual azithromycin distribution reduced mortality among children 1–59 months of age in
a large cluster-randomized trial in Malawi, Niger, and Tanzania (MORDOR trial, “Macrolides
Oraux pour Réduire les Décès avec un Oeil sur la Résistance”) [1,2]. The strongest effects were
observed in Niger, which had the highest baseline mortality rates, and in children 1–11 months
of age [1]. In conjunction with existing child survival activities, this intervention has the poten-
tial to bolster progress in reducing under-5 mortality, particularly in high-mortality settings.
However, these distributions increase the prevalence of antimicrobial resistance [3,4]. Limiting
antibiotic distributions to smaller subgroups at the highest risk of mortality might be an
approach to reduce selection for resistance [5].
Malnutrition is implicated in up to 45% of all childhood deaths globally [6]. Malnourished
children are at increased risk of mortality from infectious diseases such as diarrhea and respi-
ratory tract infections [6]. Moreover, the relationship between malnutrition and infection is
complex, with undernutrition suppressing the immune system and increasing the risk of infec-
tion, and infection causing a reduction in appetite, malabsorption of nutrients, and competi-
tion for nutrients [7,8], Provision of antibiotics to malnourished children could lead to
clearance of both overt and subclinical infections associated with mortality. Use of antibiotics
with a long half-life, like azithromycin, could also prevent the development of infections dur-
ing the 1–2 weeks after administration [9]. Other proposed mechanisms for a beneficial effect
of antibiotics in undernourished children involve modulation of the intestinal microbiota,
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which could result in a reduction in gut flora that compete for nutrients and affect chronic
conditions like environmental enteropathy [8,10–14].
Multiple studies have examined the role of antibiotics in malnourished children, with vary-
ing results. Three individual-randomized trials have compared antibiotics to placebo in the
management of severe acute malnutrition [12,15,16]. One trial in Malawi found that children
receiving antibiotics experienced greater nutritional recovery and less mortality than those
receiving placebo [15], whereas two other trials found no difference in either nutritional recov-
ery or mortality between arms [12,16]. Fewer studies have focused on children with moderate
malnutrition, although one multi-country trial evaluating the effect of antibiotics on a number
of outcomes in children with moderate acute malnutrition is currently underway [17].
Targeting high-risk subgroups such as malnourished children with azithromycin could pre-
serve resources and lower the risk of selecting for antimicrobial resistance. However, evidence
on the effect of antibiotics on mortality in malnourished children is mixed. The MORDOR
trial provides an opportunity to examine the role of antibiotics in reducing mortality in mal-
nourished children in a sub-Saharan African setting. The objective of this subgroup analysis
was to assess whether the effect of biannual distribution of oral azithromycin on child mortal-
ity differed by nutritional status in Niger.
Methods
Trial design, setting, and participants
MORDOR was a large, simple, multisite cluster-randomized trial designed to compare the
effect of biannual distribution of oral azithromycin to placebo on child mortality [1]. The pro-
tocol and statistical analysis plan for the main trial have been published, and the analyses pre-
sented here are exploratory [1]. This analysis included the Niger site, which enrolled
communities in the Boboye and Loga districts (now Boboye, Loga, and Falmey districts after
nation-wide redistricting). Communities with populations between 200 and 2,000 inhabitants
according to the Niger 2012 census were eligible for inclusion in the main trial. Children 1–59
months of age who weighed� 3.8 kg were eligible for treatment. This subgroup analysis
included children 1–11 months old who had weight recorded at the time of the child’s first
census, which could have been in any one of the censuses. Children 12–59 months old were
excluded because crude height intervals were used to determine dose in children able to stand,
and nutritional status indicators could not be accurately calculated for this group.
Ethical approval for the Niger site was obtained from the Niger Ministry of Health and the
University of California, San Francisco Committee on Human Research. Verbal informed
consent was obtained from households and caregivers before inclusion. The trial was con-
ducted in accordance with the principles of the Declaration of Helsinki and was registered at
Clinicaltrials.Gov (NCT02047981).
Census
A door-to-door census was conducted every 6 months to enumerate households in the study
area between December 2014 and August 2017. Demographic information (age, sex) was
recorded for each child 1–59 months old. During follow-up census data collection, vital status
(alive, dead, or unknown) and residence (living in community, moved outside community, or
unknown) were recorded. Five censuses (four inter-census periods) were completed during
the 2-year study. Data were collected electronically using a custom-designed mobile applica-
tion (Conexus, Los Gatos, CA) and uploaded to a cloud-based server (Salesforce, San Fran-
cisco, CA).
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Interventions
At every biannual census, each child 1–59 months old was offered a single, directly observed dose
of oral azithromycin or placebo (Pfizer, New York, NY). Children were given a dose of 20 mg per
kg, which was assessed by height-stick approximation according to Niger’s trachoma program
guidelines or by weight for children unable to stand. Children known to be allergic to macrolides
were not treated. Adverse events were monitored and have been reported elsewhere [1,18].
Outcomes
The outcome for this analysis is mortality, defined as community mortality rate (deaths per
1,000 person-years at risk). Data collected during the biannual census were used to assess the
outcome. A death was included if a child was recorded as alive on one census and died at the
subsequent census. Person-time at risk was calculated as the number of days between consecu-
tive census periods or until death. Children who moved or had an unknown status at the sub-
sequent census contributed half of the days during that inter-census period.
Assessment of nutritional status
The trial protocol included assessment of weight for the purpose of determining dosage in chil-
dren unable to stand. Trained study personnel recorded weight (if measured) and dose admin-
istered for all children in the mobile application. To determine dosage, children unable to
stand were weighed (Amw-tl440 digital hanging scale, American Weigh Scales, Cumming,
GA), and weight was recorded to the nearest 0.1 kg. A single weight measurement was taken at
each visit. Age- and sex-adjusted weight-for-age Z-scores (WAZs) were calculated using the
2006 WHO Child Growth Standards with the zscorer package in R (R Foundation for Statisti-
cal Computing, Vienna, Austria) [19–21]. WAZ was dichotomized to group children without
or with moderate to severe malnutrition (WAZ� −2 and WAZ < −2, respectively) and with-
out or with severe malnutrition (WAZ� −3 and WAZ< −3, respectively). These categories
were chosen to align with current classification standards used in nutritional policies and pro-
grams. Children with a baseline WAZ of less than −6 or greater than 5 were excluded accord-
ing to WHO recommendations [20]. As WAZ was calculated after program completion,
underweight children were not actively identified during the study period, and no additional
measures were taken to address nutritional status during the trial.
Randomization and masking
Within each country, communities were randomized 1:1 to receive biannual azithromycin or
placebo. The randomization sequence was generated in R by the trial biostatistician and was
implemented by unmasked members of the data team and Pfizer. The allocation was concealed
by simultaneous randomization assignment. Participants, investigators, data collectors, and
data analysts were masked to treatment assignment. Placebo was packaged to be identical in
appearance to the azithromycin to maintain masking.
Sample size and statistical methods
The MORDOR trial was designed and powered for the primary outcome, which has been pre-
viously published [1]. Briefly, the overall trial had 80% power to detect a 10% difference in all-
cause mortality among communities receiving azithromycin compared to placebo, and the
Niger site included 594 eligible communities [1]. Given the fixed design, the prevalence of
moderate to severe and severe underweight, and the mortality rates within subgroups, this sub-
group analysis had 80% power to detect additive interaction effects of the following sizes,
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interpreted as the mortality rate among underweight children receiving placebo in excess of
the individual effects of underweight or placebo on mortality: 17 deaths per 1,000 person-years
for the moderate to severe subgroup and 25 deaths per 1,000 person-years for the severe sub-
group [22].
Analyses were conducted in R. Participant characteristics, WAZ, and outcomes were sum-
marized by arm using frequency and percentage for categorical variables, mean and standard
deviation for continuous variables, and incidence rate (deaths per 1,000 person-years, hereafter
referred to as “mortality rate”) and 95% confidence interval for outcomes. Confidence intervals
were constructed using percentiles from bootstrap resampling with 1,000 replicates. Partici-
pant characteristics were also compared among those included in the analysis and those
excluded for having missing or invalid weight measurements. No multiple comparisons cor-
rections were made.
Effect modification was evaluated non-parametrically with interaction contrasts [23]. To
calculate the contrasts, subgroups were coded such that the groups with the lowest mortality
rates were the reference categories (i.e., R00 = mortality rate among higher-weight children in
communities assigned to azithromycin, R01 = mortality rate among underweight children in
communities assigned to azithromycin, R10 = mortality rate among higher-weight children in
communities assigned to placebo, and R11 = mortality rate among underweight children in
communities assigned to placebo) [24]. An additive interaction contrast greater than 0 indi-
cates the joint effect of receiving placebo and being underweight is greater than the sum of the
individual effects considered separately. A multiplicative interaction contrast greater than 1
indicates the joint effect of receiving placebo and being underweight is greater than the prod-
uct of the individual effects considered separately. The absolute number of deaths averted with
azithromycin in each subgroup was also estimated using person-time at risk in both arms and
the subgroup-level mortality rates.
Several sensitivity analyses were conducted. Survival probability was summarized by treat-
ment arm and WAZ subgroup using Kaplan-Meier survival curves. Effect modification was
also examined using Cox proportional hazards models. To determine the presence of multipli-
cative interaction, models included a shared frailty assuming a gamma distribution to account
for clustering, the Efron method for ties, and treatment and WAZ as covariates with their
product as an interaction term. Model estimates were reported with hazard ratios for each sub-
group against a single reference category and with hazard ratios for the effect of treatment
within each stratum of WAZ [23,25]. The estimated hazard ratios were used to calculate the
Relative Excess Risk due to Interaction (RERIHR) to assess the presence and direction of addi-
tive interaction, with the same coding as used for the interaction contrasts [23–26]. The delta
method was used to calculate standard errors for the RERIHR [23]. As treatment arm was ran-
domized and is the primary intervention of interest, confounding of the relationship between
nutritional status and mortality was not considered, and no additional factors were controlled
for in the models [23]. Model assumptions were evaluated graphically with ln(-ln) survival
plots and analytically with tests of scaled Schoenfeld residuals as well as with models including
terms for interactions with time to event for each covariate. The appropriateness of the distri-
butional assumptions for the shared frailty were assessed by comparing results against models
using a lognormal distribution for the shared frailty and estimated with generalized estimating
equations (GEEs) to account for clustering.
Additional sensitivity analyses included evaluating the potential for bias introduced by the
selection of the analysis sample by restricting the analysis to children eligible during the first
inter-census period only and by restricting to children 1–5 months of age. To assess the impact
of the use and form of WAZ, baseline weight, age, and sex were included in the models, and
baseline WAZ was assessed in continuous form. To evaluate assumptions made in determining
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time to mortality when no exact date was available, an interval censoring method was also
used. This was implemented as a generalized linear mixed model, with a binary outcome for
death, a complementary log-log link, a term for inter-census period, and a random effect for
community.
Results
In December 2014, 615 communities in Niger were randomized to receive biannual azithro-
mycin or placebo in the main trial, of which 594 communities were successfully censused and
included in analyses (Fig 1). Treatment coverage among children 1–59 months old was greater
than 91% over the 4 inter-census periods in both arms. The final sample for this analysis
included 593 communities with 27,222 children 1–11 months old who had a valid weight
recorded at the time of the child’s first entry into the study. One community was not included
because it had no eligible children, and 12,086 children 1–11 months old at their first census
were excluded either for having no weight recorded (11,899 children, of which 10,271 had
approximate height measured) or having a WAZ less than −6 or greater than 5 recorded (187
children). Over the 2-year study period, 5,189 children were lost to follow-up, with a similar
percentage of children lost in each arm.
Characteristics of included children at the time of the child’s first census are shown by treat-
ment arm in Table 1. Overall, the median age was 4 months (interquartile range [IQR] 3–6),
and 49.5% of children (13,484/27,222) were female. Mean WAZ was −0.8 (SD 1.7), with 23.0%
(6,268/27,222) of all children having a WAZ< −2 and 10.1% (2,755/27,222) having a WAZ <
−3. All characteristics were similar in both arms. Excluded children were older than included
children (median age 9 months, IQR 6–11), and a similar percentage were female (49.1%; S1
Table).
The analysis included 1,184 deaths and a total of 30,852 person-years at risk (Table 2). The
overall difference in the incidence of mortality comparing communities assigned to azithro-
mycin to communities assigned to placebo was −12.6 deaths per 1,000 person-years (95% CI
−18.5 to −6.9, P< 0.001). By subgroup, this difference was −17.0 (95% CI −28.0 to −7.0,
P = 0.001) among those with WAZ< −2, and −25.6 (95% CI −42.6 to −9.6, P = 0.003) among
those with WAZ < −3. Fig 2 compares mortality rates by treatment arm and subgroup. Inter-
action contrasts on the additive scale were 5.7 deaths per 1,000 person-years (95% CI −6.4 to
16.8, P = 0.34) for the moderate to severe subgroup and 14.4 deaths per 1,000 person-years
(95% CI −2.2 to 31.1, P = 0.14) for the severe subgroup. On the multiplicative scale, these con-
trasts were 1.1 (95% CI 0.8 to 1.4, P = 0.50) and 1.2 (95% CI 0.9 to 1.7, P = 0.26), respectively.
The estimated number of deaths averted with azithromycin among children 1–11 months old
was 388 (95% CI 214 to 574) overall, 116 (95% CI 48 to 192) among children with WAZ < −2,
and 76 (95% CI 27 to 127) among children with WAZ < −3.
Figs 3 and 4 display survival probabilities by arm and subgroup, and Table 3 reports model-
based estimates of mortality and effect modification by subgroup. Among children in placebo-
treated communities, lower WAZ was associated with an increased hazard of mortality (HR
1.32, 95% CI 1.11–1.57, P = 0.002 comparing WAZ < −2 to WAZ� −2 and HR 1.56, 95% CI
1.25–1.95, P< 0.001 comparing WAZ < −3 to WAZ� −3). The hazard for mortality was
lower in communities assigned to azithromycin than communities assigned to placebo, with a
more pronounced effect for the subgroups of underweight children (27% lower in WAZ� −2,
95% CI 15–38, P< 0.001; 30% lower in WAZ < −2, 95% CI 11–45, P = 0.003; and 38% lower
in WAZ < −3, 95% CI 14–55, P = 0.005). When comparing underweight children in commu-
nities assigned to azithromycin to higher-weight children in communities assigned to placebo,
the hazards for mortality were similar in both subgroups (HR 0.93, 95% CI 0.75–1.14, P = 0.48
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Fig 1. CONSORT participant flow diagram. CONSORT, Consolidated Standards of Reporting Trials.
https://doi.org/10.1371/journal.pmed.1003285.g001
PLOS MEDICINE Biannual azithromycin and child mortality by underweight status
PLOS Medicine | https://doi.org/10.1371/journal.pmed.1003285 September 15, 2020 8 / 17
comparing WAZ< −2 to WAZ� −2 and HR 0.97, 95% CI 0.74–1.27, P = 0.82 comparing
WAZ < −3 to WAZ� −3). No evidence of effect modification was identified. Similar results
were found in all sensitivity analyses.
Discussion
This subgroup analysis evaluated whether the effect of biannual azithromycin distribution on
child mortality differed by underweight status in a high-mortality West African setting. Azi-
thromycin was associated with an overall 28% reduction in mortality compared to placebo in
children 1–11 months old with weight measured, similar to the age-based subgroup results
from the main trial [1]. As expected given evidence on the relationship between malnutrition
and mortality [6,27,28], lower weight for age was associated with increased mortality. The
observed time to mortality in underweight children receiving azithromycin was approximately
the same as that of higher-weight children receiving placebo. Although the absolute reduction
in mortality between arms appears larger in both underweight groups, no evidence of effect
modification by WAZ subgroup was found at the 95% confidence level. The number of deaths
averted was greatest if all children were treated with azithromycin, regardless of nutritional
status.
The nonspecific distribution of azithromycin to reduce child mortality presents an ethical
dilemma: given the strong evidence of efficacy, it may be unethical to withhold such an inter-
vention, yet the intervention’s effect on antimicrobial resistance warrants caution [29].
Increasing resistance could reduce the efficacy of essential antibiotics, potentially causing addi-
tional morbidity and mortality in the longer term. Targeting the intervention to high-risk sub-
groups is one solution to preserve resources and reduce negative consequences; targeting all
children 1–11 months in this study population required 10 times the amount of azithromycin
compared to targeting WAZ < −3. A targeted approach may also be more cost-effective than a
broader distribution strategy [30]. The assumption that targeting vulnerable subgroups results
in the greatest population health benefits has been questioned, however, since more lives are
saved by intervening on a population with a wider risk spectrum [31–33]. Here, although there





Age, months, median (IQR) 4 (3–7) 4 (3–6)
Female sex, n (%) 7,040 (49.4%) 6,444 (49.6%)
Census period of entry into study, n (%)
1 4,470 (31.1%) 4,034 (31.4%)
2 3,880 (28.3%) 3,673 (27.2%)
3 2,751 (20.0%) 2,592 (19.3%)
4 3,142 (20.6%) 2,680 (22.1%)
WAZ, mean (SD) −0.8 (1.7) −0.8 (1.7)
WAZ category, moderate to severe, n (%)
� −2 10,988 (77.1%) 9,966 (76.8%)
< −2 3,255 (22.9%) 3,013 (23.2%)
WAZ category, severe, n (%)
� −3 12,796 (89.8%) 11,671 (89.9%)
< −3 1,447 (10.2%) 1,308 (10.1%)
Abbreviations: IQR, interquartile range; WAZ, weight-for-age Z-score
https://doi.org/10.1371/journal.pmed.1003285.t001
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is some indication that intervening on those with the lowest WAZ may be particularly benefi-
cial, the absolute number of deaths averted was 5 times greater when including all children
1–11 months as opposed to only the 10% with WAZ < −3. In addition, possible indirect effects
might be lost with a more focused intervention. Finally, targeting a subgroup of the population
presents its own ethical complexity, as providing a beneficial intervention more broadly might
be more equitable when resources are available to do so [29].
Approximately 23% of the children included in this analysis were underweight, similar to
other estimates indicating that Niger bears a high burden of malnutrition [34]. A single weight
measurement was taken on a subset of children 1–11 months old who were unable to stand,
which has several implications for interpretation of these results. First, other nutritional status
indicators like wasting and stunting were not assessed, nor were the causes of underweight sta-
tus. Underweight status has been shown to increase the risk of mortality in multiple settings
[6,27,28,35,36], with some evidence demonstrating that WAZ alone is a highly sensitive and
specific indicator of concurrent wasting and stunting [37]. In addition, as malnutrition is
caused by a wide variety of factors, azithromycin might be more effective in cause-specific sub-
groups of underweight children, though this study was neither designed nor powered to assess
the effect by smaller subgroups. Similarly, as underweight status could be a proxy for other
child, household, and community characteristics, the mechanism of effect modification is
likely more complex than modeled here. Second, although being underweight at the first visit
likely predicts being underweight at later visits, we were unable to unable to examine the
impact of changing nutritional status over time. Children who became underweight after their
first visit thus might be misclassified by this analysis, which we would expect to bias any effect
modification towards the null. Third, the selection of children 1–11 months of age who had
weight measurements available could introduce bias, since children at the older end of that
range who were able to stand were more likely not to be weighed. However, exclusions among
the older age group were balanced by arm, overall and across census periods, and sensitivity
analyses restricting the population to children 1–5 months produced similar results to the
Table 2. Number of deaths, person-time at risk, and mortality rates by treatment arm and subgroups of WAZ.
















Overall 14,243 523 16,153 32.4
(29.3 to 35.5)








� −2 10,988 387 12,610 30.7
(27.0 to 34.4)






< −2 3,255 136 3,543 38.4
(32.4 to 44.9)







� −3 12,796 460 14,599 31.5
(28.3 to 35.0)






< −3 1,447 63 1,554 40.5
(30.9 to 49.7)






1Deaths per 1,000 person-years at risk.
2Confidence intervals calculated using bootstrap resampling at the community level to account for clustering; 1,000 replicates were used.
Abbreviation: WAZ, weight-for-age Z-score
https://doi.org/10.1371/journal.pmed.1003285.t002
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main analysis. Additionally, older children were not weighed. The analysis population thus
might not be representative of the general population, as it might include a higher prevalence
of underweight children and does not reflect the experience of children 12–59 months old.
Fourth, the SD for WAZ was greater than 1 [20], likely due to measurement error since weight
was assessed primarily for the purpose of intervention delivery. Only one measurement was
taken at each visit for each child in order to determine dosage. As mean WAZ and SD were
similar across arms, any information bias is likely to be conservative, which could have masked
the presence of effect modification. Fifth, both mortality and malnutrition are known to vary
seasonally in West Africa [38,39]. Seasonality-focused analyses were not pursued given the low
Fig 2. Comparison of mortality rates by treatment arm and WAZ subgroup with interaction contrasts. (A, B) Comparisons of mortality rate (deaths per 1,000
person-years) by treatment arm overall and by WAZ subgroup on the additive (A) and multiplicative (B) scales. (A) Mortality rate differences (mortality rate in
communities assigned to azithromycin minus mortality rate in communities assigned to placebo). (B) Mortality rate ratios (mortality rate in communities assigned to
azithromycin divided by mortality rate in communities assigned to placebo). (C, D) Interaction contrasts on the additive (C) and multiplicative (D) scales. Interaction
contrasts defined subgroups such that the groups with the lowest mortality rates were the reference categories (i.e., R00 = mortality rate among higher-weight children in
communities assigned to azithromycin, R01 = mortality rate among underweight in communities assigned to azithromycin, R10 = mortality rate among higher-weight
children in communities assigned to placebo, and R11 = mortality rate among underweight children in communities assigned to placebo). (C) Interaction contrasts on
the additive scale. (D) Interaction contrasts on the multiplicative scale. WAZ, weight-for-age Z-score.
https://doi.org/10.1371/journal.pmed.1003285.g002
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power to further stratify the population, and the lack of an overall seasonal effect of azithromy-
cin on mortality in the main trial [39]. Finally, the use of cutoffs to categorize malnourished
groups has been criticized for creating a false separation of subgroups in which to intervene
[40], particularly in high-burden areas where the entire distribution of anthropometric indica-
tors is shifted downwards. As these cutoffs are actively used in current programs and policy,
their use in this application provides readily available information to these sectors while also
calling into question the impact of a targeted strategy that would exclude many children with
mild to moderate malnutrition who also face an increased burden of mortality [27].
Additional limitations of this study include those shared by most subgroup analyses of tri-
als, such as the potential for false negatives from lack of power and bias from use of improper
subgroups. The effect sizes observed in this analysis were smaller than detectable by the design
(5.7 versus 17 deaths per 1,000 person-years for the moderate to severe subgroup, and 14.4 ver-
sus 25 deaths per 1,000 person-years for the severe subgroup), indicating the analysis was
Fig 3. Kaplan-Meier estimates of survival probability by treatment arm and the moderate to severe underweight subgroup. Each curve depicts a different
subgroup, with placebo represented by dotted lines in shades of blue and azithromycin represented by solid lines in shades of red. The darker shades indicate the higher-
weight subgroup (WAZ� −2), and the lighter shades indicate the underweight subgroup (WAZ< −2). The y-axis is broken for clarity and jumps from 0.00 to 0.85.
WAZ, weight-for-age Z-score.
https://doi.org/10.1371/journal.pmed.1003285.g003
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underpowered. The use of baseline WAZ from children who entered the study after azithro-
mycin had been distributed at the community level could result in bias since WAZ for these
children is a post-randomization characteristic that could be influenced by treatment arm. A
sensitivity analysis restricted to the first phase of the study did not reveal differences in results.
Also, underweight prevalence did not differ by arm across census period, so more complex
approaches to assessing or controlling for this potential bias were not pursued. In this type of
dynamic cohort, differential loss to follow-up can result in selection bias. Although loss to fol-
low-up was present, it was similar when compared by arm. Further research would be required
to determine whether these results were generalizable to settings beyond those similar to
Niger, which has a high burden of both malnutrition and mortality. Strengths of this study
include the large sample size, the assessment of both additive and multiplicative interaction,
and the randomized design.
Fig 4. Kaplan-Meier estimates of survival probability by treatment arm and the severe underweight subgroup. Each curve depicts a different subgroup, with
placebo represented by dotted lines in shades of blue and azithromycin represented by solid lines in shades of red. The darker shades indicate the higher-weight
subgroup (WAZ� −3), and the lighter shades indicate the underweight subgroup (WAZ< −3). The y-axis is broken for clarity and jumps from 0.00 to 0.85. WAZ,
weight-for-age Z-score.
https://doi.org/10.1371/journal.pmed.1003285.g004
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In summary, a placebo-controlled trial found that biannual azithromycin distribution
reduced mortality among children 1–11 months old regardless of underweight status.
Although the observed mortality reduction with azithromycin was larger among subgroups of
underweight children, underweight status was not a statistically significant effect modifier in
this trial. Treatment of all children 1–11 months old would save 5 times as many lives as
restricting treatments only to children with a WAZ < −3.
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